Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced Genedata Analyst™, an integrated statistical and data analysis platform with advanced visualization capabilities. Built on client-server architecture, Genedata Analyst handles huge and complex data sets of billion-plus data points while supporting small research groups or hundreds of users. Simultaneously managing data from different sources, Genedata Analyst gives researchers and biostatisticians a secure and scalable data-mining platform, which can be tightly integrated with existing research IT ecosystems. New to the Genedata solutions portfolio, Genedata Analyst will be demonstrated at the Society of Toxicology 49th Annual Meeting’s ToxExpo (March 8 -10; Booth #1837).
“As a non-bioinformatics person analyzing large gene expression datasets, it is critical that software be both powerful yet have a biologist-friendly interface,” noted Dr. Kathie-Anne Walters with The Institute for Systems Biology, an internationally renowned, non-profit research institute dedicated to the study and application of systems biology. “Genedata Analyst fulfills these requirements. In addition, its ease of use is an added benefit. With minimal training, it was possible to load data, perform a variety of normalization steps and quickly start interrogating and visualizing the data thereby giving us the ability to identify relationships in datasets that might otherwise not be identified.”
Statistical Analysis for All Scientists
A standalone solution with predefined workflows, Genedata Analyst gives a broad range of scientists the capabilities for sophisticated data analysis. Combining the management of diverse data sources and types with data mining tools and knowledge management systems, Genedata Analyst provides a comprehensive set of statistical approaches and interfaces to third-party algorithms. Features include:
“Through years of working with our customers in pharmaceutical and life science research, we’ve seen that separate tools for data mining and statistical analysis combined with the inability to integrate data from different sources creates costly and time-consuming inefficiencies and bottlenecks,” said Dr. Othmar Pfannes, CEO of Genedata. “Genedata Analyst addresses these challenges by giving our customers a new data analysis platform that combines validated statistics, proven user workflows, and established visualization technologies. We believe Genedata Analyst is truly game changing for life science research as it delivers a data mining platform that enables all user groups to perform powerful data integration and aggregation.”
[Note to Editors: Mark your calendars for the Genedata Analyst product session at SOT on March 9, 8:30am – 9:30am, Room 155F. To schedule a briefing and product demo email: Jackie.email@example.com]
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US. www.genedata.com
Marketing & Communications
Phone: +41 61 511 8459
Phone: +1 508 881 3109
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.